Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06608901 · ClinicalTrials.gov registry record · Phase 2
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
A Phase 2 study of Sepsis-Induced Hypotension, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT06608901: Active Phase 2 study of Sepsis-Induced Hypotension, sponsored by Regeneron Pharmaceuticals.
NCT06608901 is a Phase 2 study of Sepsis-Induced Hypotension that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 76 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06608901, a Phase 2 study of Sepsis-Induced Hypotension, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sepsis. The aim of the study is to see how safe, tolerable, and effective the study drug is by observing the effects on blood pressure and the total amount of vasopressor dose received during the stay in the hospital. The study is looking at several other research questions, including: * How the study drug changes the blood pressure and the amount of intravenous (IV) fluids given to participants with low blood pressure due to sepsis * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG REGN7544
- DRUG PB
Study Locations (20)
New York
- New York University Langone Health Brooklyn Hospital - Brooklyn
- Bellevue Hospital - New York
- New York University Langone Health Tisch-Kimmel Hospital - New York
- Montefiore Medical Center - Weiler Hospital - The Bronx
- Montefiore Medical Center - Moses Campus - The Bronx
Massachusetts
- Massachusetts General Hospital - Boston
- Harvard Medical School - Beth Israel Deaconess Medical Center - Boston
Arizona
- University of Arizona - Tucson
Connecticut
- Yale University - New Haven
Georgia
- Emory University Hospital - Atlanta
Maryland
- Johns Hopkins Hospital - Baltimore
North Carolina
- Atrium Health - Winston-Salem
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
What the registry record for NCT06608901 still lists
NCT06608901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Sepsis-Induced Hypotension appearing as the primary indexed condition, and to 2 interventions - of which REGN7544 is the first listed.
NCT06608901 names 20 study sites across 15 states, led by New York, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT06608901 about?
NCT06608901 is a clinical study titled "A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension". This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sep...
What is the current status of trial NCT06608901?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2025-05-05. Estimated completion is 2026-04-30.
What conditions does trial NCT06608901 study?
This clinical trial studies the following conditions: Sepsis-Induced Hypotension.
What interventions are being tested in trial NCT06608901?
The interventions under investigation include: REGN7544 (DRUG), PB (DRUG).
Who is sponsoring clinical trial NCT06608901?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06608901 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06608901's enrollment target sits among peer trials
76 893rd of 2000 higher than 1,101 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI